Logo

Log In Sign Up |  An official publication of: American College of Emergency Physicians
Navigation
  • Home
  • Multimedia
    • Podcasts
    • Videos
  • Clinical
    • Airway Managment
    • Case Reports
    • Critical Care
    • Guidelines
    • Imaging & Ultrasound
    • Pain & Palliative Care
    • Pediatrics
    • Resuscitation
    • Trauma & Injury
  • Resource Centers
    • mTBI Resource Center
  • Career
    • Practice Management
      • Benchmarking
      • Reimbursement & Coding
      • Care Team
      • Legal
      • Operations
      • Quality & Safety
    • Awards
    • Certification
    • Compensation
    • Early Career
    • Education
    • Leadership
    • Profiles
    • Retirement
    • Work-Life Balance
  • Columns
    • ACEP4U
    • Airway
    • Benchmarking
    • Brief19
    • By the Numbers
    • Coding Wizard
    • EM Cases
    • End of the Rainbow
    • Equity Equation
    • FACEPs in the Crowd
    • Forensic Facts
    • From the College
    • Images in EM
    • Kids Korner
    • Medicolegal Mind
    • Opinion
      • Break Room
      • New Spin
      • Pro-Con
    • Pearls From EM Literature
    • Policy Rx
    • Practice Changers
    • Problem Solvers
    • Residency Spotlight
    • Resident Voice
    • Skeptics’ Guide to Emergency Medicine
    • Sound Advice
    • Special OPs
    • Toxicology Q&A
    • WorldTravelERs
  • Resources
    • ACEP.org
    • ACEP Knowledge Quiz
    • Issue Archives
    • CME Now
    • Annual Scientific Assembly
      • ACEP14
      • ACEP15
      • ACEP16
      • ACEP17
      • ACEP18
      • ACEP19
    • Annals of Emergency Medicine
    • JACEP Open
    • Emergency Medicine Foundation
  • About
    • Our Mission
    • Medical Editor in Chief
    • Editorial Advisory Board
    • Awards
    • Authors
    • Article Submission
    • Contact Us
    • Advertise
    • Subscribe
    • Privacy Policy
    • Copyright Information

Oral Vancomycin Curbs C. difficile Recurrence in Some Patients

By Scott Baltic | on November 22, 2016 | 0 Comment
ED Critical Care Uncategorized
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
Print-Friendly Version

They added, however, that in the context of secondary prophylaxis, where C. difficile load is minimal, a lower vancomycin dosage, such as 125 mg once or twice daily, might remain effective, while minimizing disruption of normal flora, but that dosage would require further study. (The most common vancomycin dosage in this study was 125 mg four times a day.)

You Might Also Like
  • Early Fecal Transplant Improves Survival after Severe C. Diff Infection
  • Experimental Antibody Reduces Risk of C. difficile Recurrence
  • How to Minimize Diarrhea Risk for Patients Taking IV Antibiotics

Pages: 1 2 | Single Page

Topics: AntibioticsClostridium difficileCritical CareinfectionInfectious DiseasePatient CareResearch

Related

  • Why the Nonrebreather Should be Abandoned

    December 3, 2025 - 0 Comment
  • Let Core Values Help Guide Patient Care

    November 5, 2025 - 0 Comment
  • Non-Invasive Positive Pressure Ventilation in the Emergency Department

    October 1, 2025 - 0 Comment

Current Issue

ACEP Now: November 2025

Download PDF

Read More

No Responses to “Oral Vancomycin Curbs C. difficile Recurrence in Some Patients”

Leave a Reply Cancel Reply

Your email address will not be published. Required fields are marked *


*
*


Current Issue

ACEP Now: November 2025

Download PDF

Read More

Polls

Which topic would you like to see ACEP Now tackle?

View Results

Loading ... Loading ...
  • Polls Archive
Wiley
  • Home
  • About Us
  • Contact Us
  • Privacy
  • Terms of Use
  • Advertise
  • Cookie Preferences
Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 2333-2603